Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 16, 2026

Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain?

View original at finance.yahoo.com
“The latest twelve month free cash flow is about US$23.94b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shell scores 4 out of 6 on Simply Wall St's valuation checks, suggesting it screens as undervalued on most, but not all, metrics

    60% confidence

  • DCF analysis suggests Shell is undervalued by 54.0% with an estimated intrinsic value of US$72.77 per share compared to current price of £33.46

    60% confidence

  • Analyst forecasts and Simply Wall St extrapolations indicate free cash flow of US$27.30b in 2030

    60% confidence

Data points we hold from this source

Shell plc · stock return 1w-1.6 percent
Shell plc · stock return ytd21.3 percent
Shell plc · stock return 1y43.0 percent
Shell plc · stock return 1m-2.0 percent
Shell plc · free cash flow23.94 USD
Shell plc · free cash flow forecast27.30 USD
Shell plc · valuation score4 out_of_6
Shell plc · intrinsic value dcf72.77 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain? — Source | Via News | ViaNews EU